MAP2K7 and metastatic melanoma: The combination of a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) increases the expression of KIT, a tumor suppressor, and also induces alterations in CCND1, RB1, and MET in patients with BRAFV600E metastatic melanoma (Louveau et al., 2019).